NDATOPICALLOTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRYHALI is a topical lotion formulation of halobetasol propionate, a potent corticosteroid approved in 2018 for the treatment of plaque psoriasis. The drug works through signaling, immune function, inflammation, and protein regulation mechanisms, though its precise mechanism of action in psoriasis remains unknown. It represents a branded topical corticosteroid option in a mature dermatology market.
$0.142MPart D
Peak5.5 years to LOEBRYHALI is in peak commercial stage with modest Part D spending, suggesting a stable but niche dermatology brand with limited sales team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Career Relevance
BRYHALI roles are primarily commercial-focused, centered on maintaining market share in a competitive topical corticosteroid space. Career progression on this brand is limited due to modest spending ($142K in Part D), zero linked job openings, and mature product status with no active R&D pipeline.
Brand Manager
Worked on BRYHALI at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.